Literature DB >> 28586242

Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Ahmet Emre Eskazan1, Deniz Ozmen1.   

Abstract

Entities:  

Keywords:  Adverse event; bosutinib; chronic myeloid leukemia; dasatinib; first-line; imatinib; nilotinib; ponatinib; response; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2017        PMID： 28586242     DOI： 10.1080/17474086.2017.1339599

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


× No keyword cloud information.
  7 in total

1.  Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2019-08-22       Impact factor: 4.335

2.  Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

3.  [Effect of bortezomib in inducing apoptosis of imatinib-resistant K562 cells and the mechanism].

Authors:  Jia-Ye Hua; Xu-Hong Zhou; Shu-Ting Ouyang; Yong-Bin Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

4.  Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.

Authors:  Ahmet Emre Eskazan
Journal:  Int J Clin Oncol       Date:  2017-11-13       Impact factor: 3.402

5.  Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

Authors:  Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2020-05-20       Impact factor: 4.335

Review 6.  Alterations in cellular metabolisms after Imatinib therapy: a review.

Authors:  Veerandra Kumar; Priyanka Singh; Sonu Kumar Gupta; Villayat Ali; Malkhey Verma
Journal:  Med Oncol       Date:  2022-05-16       Impact factor: 3.064

7.  Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis.

Authors:  Hiroyuki Iwasaki; Soji Toda; Daisuke Murayama; Shin Kato; Ai Matsui
Journal:  Mol Clin Oncol       Date:  2020-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.